SUBSCRIBE
SUBSCRIBE

Phase II

Vutrisiran can be Alnylam's fourth drug approval.
Drug Development
Alnylam Poised for Fourth Drug Approval with Strong Phase III hATTR Results of Vutrisiran
This morning, Alnylam announced vutrisiran met primary and all secondary endpoints. Here’s everything you need to know about the drug and its purpose.
January 7, 2021
 · 
3 min read
 · 
Alex Keown
Drug Development
Six Life Sciences Successes and Failures To Kick Off 2021
2021 is off to a hopeful start for some companies, executives and scientists, while others are forced to fold programs and recalibrate.
January 5, 2021
 · 
6 min read
 · 
Heather McKenzie
Drug Development
2021 Biopharma Update on the Novel Coronavirus: January 5
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 5, 2021.
January 4, 2021
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Calithera Cutting 35% of Workforce After Kidney Cancer Trial Failure
Calithera Biosciences reported that its CANTATA clinical trial of telaglenastat in patients with advanced or metastatic renal cell carcinoma (RCC) failed to hit the primary endpoint.
January 4, 2021
 · 
3 min read
 · 
Mark Terry
BioCapital
Clinical Catch-Up: December 21-25
Even with the holidays among us, there were a number of clinical trial announcements. Here’s a look.
December 23, 2020
 · 
9 min read
 · 
Mark Terry
Jason Armond / Los Angeles Times via Getty Images
Drug Development
Voyager Takes a Hit After FDA Places Hold on Gene Therapy for Parkinson’s Disease
In October, the FDA placed a clinical hold on the company’s Huntington’s disease gene therapy before that asset could make its way into the clinic.
December 23, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: December 29
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 29, 2020.
December 22, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: December 22
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.
December 22, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Masitinib showing its capabilities in late stage A
Drug Development
AB Science’s Masitinib Shows Unusually Good Data in Late-Stage Alzheimer’s Trial
AB Science SA reported promising data from its Phase IIb/III trial of masitinib in patients with confirmed mild to moderate Alzheimer’s disease.
December 18, 2020
 · 
3 min read
 · 
Mark Terry
Drug Development
Clinical Catch-Up: December 14-18
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
December 18, 2020
 · 
13 min read
 · 
Mark Terry
Load More
PRESS RELEASES
Drug Development
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
May 22, 2024
 · 
11 min read
Drug Development
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
May 22, 2024
 · 
6 min read
Drug Development
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
May 22, 2024
 · 
6 min read
Drug Development
Noema Pharma Announces First Patient Dosed in Phase 2a Study of NOE-115, a First-In-Class Investigational Therapy for the Treatment of Vasomotor Symptoms and Additional Symptoms Associated with Menopause
May 22, 2024
 · 
3 min read
Drug Development
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
May 22, 2024
 · 
7 min read
Drug Development
Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity
May 22, 2024
 · 
12 min read
Drug Development
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
May 21, 2024
 · 
9 min read
Drug Development
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
May 21, 2024
 · 
8 min read
Drug Development
Imvax Announces Completion of Enrollment in Phase 2b Clinical Trial of IGV-001 and Successful Financing
May 21, 2024
 · 
5 min read
Drug Development
Molecure receives approval to initiate a Phase II clinical trial (KITE) for OATD-01 for the treatment of pulmonary sarcoidosis in selected countries of the European Union and Norway
May 21, 2024
 · 
6 min read
Drug Development
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
May 21, 2024
 · 
4 min read
Drug Development
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
May 21, 2024
 · 
6 min read
Drug Development
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
May 21, 2024
 · 
6 min read
Drug Development
Cali Biosciences Announces Publication of Successful Phase 2 Study Results in Hernia
May 21, 2024
 · 
3 min read
Business
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
May 20, 2024
 · 
6 min read
Drug Development
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
May 20, 2024
 · 
6 min read
Business
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer
May 20, 2024
 · 
6 min read
Drug Development
Anokion Announces New Clinical Data from the Phase 1b/2 ACeD-it Trial Supporting KAN-101 as a Potential Disease-Modifying Treatment for Celiac Disease
May 20, 2024
 · 
3 min read
Drug Development
NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease
May 20, 2024
 · 
6 min read
Drug Development
Allarity Therapeutics Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement
May 20, 2024
 · 
5 min read
Load More